Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab

Published:2023-05 Issue:4 Volume:55 Page:878-883
ISSN:0041-1345
Container-title:Transplantation Proceedings
language:en
Short-container-title:Transplantation Proceedings

Author:

Kuo Fang-Cheng,Chen Cheng-Yen^ORCID,Lin Niang-Cheng,Liu Chinsu,Hsia Cheng-Yuan,Loong Che-Chuan

Publisher

Elsevier BV

Subject

Transplantation,Surgery

Reference29 articles.

1. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J Hepatol,2022

2. CTLA-4 and PD-1 pathways;Buchbinder;Am J Clin Oncol,2016

3. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?;Nordness;Am J Transplant,2020

4. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period;Chen;Transpl Immunol,2021

5. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review;Fisher;J Am Acad Dermatol,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fatal graft-versus-host disease in recipient with pretransplant exposure to immune checkpoint inhibitors and donor-dominant one-way HLA matching after liver transplantation: A case report;International Journal of Surgery Case Reports;2024-10

2. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?;World Journal of Gastrointestinal Pharmacology and Therapeutics;2024-09-05

3. Immunotherapy Prior to a Liver Transplant: Literature Review and a Case Report of Hepatocellular Carcinoma With BRCA1 Mutation;Innovative Medicine of Kuban;2024-08-23

4. Harnessing the Power of Immunotherapy in Liver Transplantation for HCC;Current Transplantation Reports;2024-07-03

5. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis;Journal of Hepatology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3